Keywords: genzyme, develop, angiogenesis, inhibitor, molecular, oncology, atiii

Genzyme to develop angiogenesis inhibitor

Article | 20 September 1999

Print This

Genzyme Molecular Oncology and ATIII LLC, a joint venture betweenGenzyme Transgenics and Genzyme General, have signed a letter of intent ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in